Clinical trials: CMV Infection
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
CMV Infection, Hematopoietic Stem Cell Transplantation
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05656599
- Testing
- Letermovir
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Congenital CMV Infection
Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit
Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of pediatric hearing loss and an important cause of neurodevelopmental delay.
- Trial name
- NCT02680743
- Testing
- Education of parents to pursue prompt hearing screening.
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Nebraska
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
CMV Infection, Hematopoietic Stem Cell Transplantation
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
- Trial name
- NCT06021210
- Testing
- Letermovir Pill
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
To evaluate the efficacy and safety of primary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese R+ haplo-HSCT patients, as well as treatment-related mortality and all-cause…
- Trial name
- NCT05914675
- Testing
- Letermovir
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Congenital Cmv
Observational Study of the Management of Infants With Congenital CMV
This is an observational, prospective/retrospective multicentre, cohort study of children diagnosed with cCMV. This study will contribute to a wider study also recruiting participants in Europe and other countries worldwide.
- Trial name
- cCMVnet (NCT05855889)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- St George's, University of London
CMV Infection After Allogenic HSCT
CMV-TCR-T Cells for CMV Infection After Allogenic HSCT
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after allogenic HSCT.
- Trial name
- NCT05140187
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chinese PLA General Hospital
CMV Infection or Reactivation After Allogenic HSCT
CMV-TCR-T Cells for CM Virus Infection After HSCT
This is a single cente, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.
- Trial name
- NCT04153279
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Hematological Malignancies, CMV Infection
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
Viral infections remain an important cause of morbidity and mortality after allogeneic stem cell transplantation (SCT), especially after myelo-ablative conditioning and if the donor is antigen-mismatched or haplo-identical..
- Trial name
- NCT03067155
- Testing
- CMV-specific T cells, Standard anti-viral therapy
- Where
- 8 sites in Belgium
- Volunteers
- 1 people
- Sponsor
- University Hospital, Ghent
CMV Viremia, Transplantation Infection
CMV Infection and Immune Intervention After Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of allo-HSCT.
- Trial name
- NCT04320303
- Testing
- expanded NK cells
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
CMV, EBV
Cytotoxic T Cells to Prevent Virus Infections
In this study, investigators are trying to see if infusion of "m-CTLs" will prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or infection after cord blood transplant.
- Conditions
- CMV, EBV, Adenovirus Infections
- Trial name
- NCT01923766
- Testing
- Cytotoxic T lymphocytes (CTLs).
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's National Research Institute
CMV Infection
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
Cytomegalovirus (CMV) infections remain an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HSCT) recipients, especially in patients received haploidentical transplantation.
- Trial name
- NCT02985775
- Testing
- Donor-derived CMVpp65-specific T cells
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Peking University People's Hospital
Congenital Cytomegalovirus (CMV)
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic neurosensory deafness and affects 0.5 to 1% of births.
- Trial name
- GANCIMVEAR (NCT02606266)
- Testing
- Valganciclovir
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Transplant Recipients With CMV Infection
A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Resistance to antivirals is a growing problem in transplantation.that may concerns up to 5% of patients treated for cytomegalovirus (CMV) syndrome or disease in recent per-protocol studies.
- Trial name
- ORPHAVIC (NCT02067169)
- Testing
- CMV Infection
- Where
- 38 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Limoges
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
CMV Infections
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02313857
- Testing
- Viralym-C
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- AlloVir
ANCA Associated Vasculitis, CMV Infection
CMV Modulation of the Immune System in ANCA-associated Vasculitis
The purpose of this study is to determine whether Cytomegalovirus (CMV) reactivation in ANCA-associated vasculitis (AAV) patients can be effectively and safely reduced using an antiviral agent (valaciclovir) and whether this in…
- Trial name
- CANVAS (NCT01633476)
- Testing
- Valaciclovir
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Professor Lorraine Harper
CMV Infection, EBV
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or…
- Conditions
- CMV Infection, EBV, Adenovirus
- Trial name
- R3ACT (NCT02779439)
- Testing
- Virus specific CTLs
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Sydney
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine